Clinical applications of Granulocyte Colony Stimulating Factor and Pirfenidone in Lung Fibrosis

Background: Granulocyte colony-stimulating factor (G-CSF), a protein that stimulates the production of new blood cells, was isolated from human cells. In the hierarchical development of hematopoiesis, G-CSF mainly drives myeloid cell series from committed progenitor cells to mature neutrophil granulocytes. Some of the important effects of G-CSF include preserving the viability of progenitor cells and their mature offspring, preventing apoptosis, encouraging cell division, determining lineage affiliation, influencing the maturation process, and enhancing phagocytosis activity. One medication that is effective in treating idiopathic pulmonary fibrosis is pirfenidone (PFD). Although it was first created as an anti-inflammatory substance due to its capacity to reduce the buildup of inflammatory cells and cytokines, it has primarily been described as an antifibrotic agent. The particular molecular activities of PFD are still not fully understood, but new research that has clarified important processes. By altering fibrogenic growth factors, PFD prevents the production of collagen and fibronectin, myofibroblast differentiation, fibroblast proliferation, and extracellular matrix deposition. This action is mediated by the suppression of TGF-β1 (transforming growth factor-β1) and other growth factors. Here, we evaluate how PFD affects the synthesis of TGF-β1 and its downstream pathways. PFD has great deal of promise as a novel and effective anti-inflammatory drug since there is growing evidence that it also inhibits inflammatory pathways. Conclusion: PFD has the ability to target inflammasome pathways, which highlights the resulting inflammation in the lungs. PFD possessed antioxidant qualities, including the capacity to control genes and enzymes linked to oxidative stress and to suppress redox processes..